FDA premarket pathways explained: 510(k), De Novo, PMA and exempt
How to choose between 510(k), De Novo, PMA and exemption — what each FDA premarket pathway requires, how long it takes, and how to tell which one fits your device.
Choosing an FDA premarket pathway is the single decision that sets your evidence burden, your timeline and your budget. It follows directly from classification, and it is worth getting right before a single test protocol is written.
The four routes
**Exempt.** Most Class I devices, and a subset of Class II, are exempt from premarket notification. Exemption is never unconditional: the classification regulation carries limitations, and expanding indications or adding a novel feature can pull an exempt device back into 510(k) territory.
**510(k) premarket notification.** The default route for Class II. You demonstrate substantial equivalence to a legally marketed predicate. Review is measured in months, and the evidence package is comparative rather than absolute.
**De Novo classification.** For low-to-moderate risk devices with no suitable predicate. Instead of comparing, you propose the special controls that make the device safe and effective. A successful De Novo creates a new classification and product code that later devices can use as a predicate.
**Premarket approval (PMA).** For Class III devices. The most demanding route: valid scientific evidence, usually including clinical data, that independently establishes safety and effectiveness.
How to tell which one fits
Start from the intended use statement and the product code. If cleared devices already sit under that code with indications you can match, 510(k) is the working assumption. If nothing cleared shares your intended use but the risk profile is moderate, De Novo is the likely route. If the device supports or sustains life, is implanted, or presents a potential unreasonable risk, plan for PMA.
The question that most often changes the answer is not technical — it is how broadly the indications are written. Narrowing the claim can move a programme from De Novo to 510(k); widening it can do the reverse.
Before you commit
Confirm the classification regulation text, pull recent clearances or grants under the candidate code, and check whether FDA has issued guidance or special controls specific to your device type. A Pre-Submission meeting is cheap relative to a rejected submission, and is the right place to test a pathway assumption.
How DevicePath helps
DevicePath is an open-source regulatory triage tool. Describe the device in plain language and it returns the likely FDA device class, candidate product codes, the probable premarket pathway, real 510(k) predicate candidates with K-numbers, and high-level EU MDR and UK (UKCA / MHRA) considerations. Use it to pressure-test a pathway assumption in seconds, then take a shortlist to regulatory counsel.